Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study

다국어 초록 (Multilingual Abstract)

Objective To validate the criteria for the extreme risk category for atherosclerotic cardiovascular disease (ASCVD).


Methods An observational cohort study of 35,464 individuals with established ASCVD was performed using the National Health Information Database. Incident myocardial infarction (MI), ischemic stroke, and death in patients with established ASCVD was investigated to validate the criteria for the extreme risk category of ASCVD defined as the presence of diabetes mellitus (DM), chronic kidney disease (CKD), and history of premature ASCVD.


Results Among 35,464 patients, 77.97% of them were classified into the extreme risk group of ASCVD. A total of 28.10%, 39.61%, and 32.12% had DM, CKD, and a history of premature ASCVD, respectively. During a mean follow-up of 8.39 years, MI, ischemic stroke, and all-cause death were found in 3.87%, 8.51%, and 23.98% of participants, respectively. In multivariate analysis, patients with DM had higher risk for MI (hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.45–1.81), ischemic stroke (HR, 1.39; 95% CI, 1.29–1.50), and all-cause death (HR, 1.52; 95% CI, 1.45–1.59) than those without DM. Patients with CKD had 1.56 times higher risk for MI, 1.12 times higher risk for ischemic stroke, and 1.34 times higher risk for death than those without CKD. However, the risk for MI, ischemic stroke, and all-cause death was not different between patients with and without a history of premature ASCVD.


Conclusion DM and CKD, but not a history of premature ASCVD, could be considered as reasonable criteria of an extreme risk for ASCVD.

참고문헌 (Reference)

1 Wilterdink JL, "Vascular event rates in patients with atherosclerotic cerebrovascular disease" 49 : 857-863, 1992

2 배재현 ; 문민경 ; 오소희 ; 구보경 ; 조남한 ; 이문규, "Validation of Risk Prediction Models for Atherosclerotic Cardiovascular Disease in a Prospective Korean Community-Based Cohort" 대한당뇨병학회 44 (44): 458-469, 2020

3 Baigent C, "The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease(Study of Heart and Renal Protection) : a randomised placebo-controlled trial" 377 : 2181-2192, 2011

4 Fellström BC, "Rosuvastatin and cardiovascular events in patients undergoing hemodialysis" 360 : 1395-1407, 2009

5 Kannel WB, "Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories" 1 : 333-339, 1994

6 Yang J, "Risk factors and outcomes of very young adults who experience myocardial infarction : the partners YOUNG-MI registry" 133 : 605-612, 2020

7 Mahtta D, "Premature atherosclerotic cardiovascular disease : What have we learned recently?" 22 : 44-, 2020

8 Cupples LA, "Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction : the Framingham Study" 125 : 863-872, 1993

9 이승환 ; 한경도 ; 김헌성 ; 조재형 ; 윤건호 ; 김미경, "Predicting the Development of Myocardial Infarction in Middle-Aged Adults with Type 2 Diabetes: A Risk Model Generated from a Nationwide Population-Based Cohort Study in Korea" 대한내분비학회 35 (35): 636-646, 2020

10 남가은 ; 김양현 ; 한경도 ; 정진형 ; 이은정 ; 이성수 ; 김대중 ; 이관우 ; 이원영 ; the Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity, "Obesity Fact Sheet in Korea, 2019: Prevalence of Obesity and Abdominal Obesity from 2009 to 2018 and Social Factors" 대한비만학회 29 (29): 124-132, 2020

11 Long A, "Non-traditional risk factors for atherosclerotic disease : a review for emergency physicians" 36 : 494-497, 2018

12 Jacobson TA, "National lipid association recommendations for patient-centered management of dyslipidemia : part 1--full report" 9 : 129-169, 2015

13 Criqui MH, "Mortality over a period of 10 years in patients with peripheral arterial disease" 326 : 381-386, 1992

14 Sun F, "Metabolic syndrome and the development of chronic kidney disease among 118 924 non-diabetic Taiwanese in a retrospective cohort" 15 : 84-92, 2010

15 김효은 ; 이찬주 ; 최동훈 ; 김병극 ; 김인철 ; 김중선 ; 안철민 ; 홍그루 ; 조인정 ; 심지영 ; 이상학, "Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin" 한국지질동맥경화학회 9 (9): 283-290, 2020

16 Virani SS, "Heart disease and stroke statistics-2020 update : a report from the American Heart Association" 141 : e139-e596, 2020

17 Rallidis LS, "Extreme-risk category : high prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL" 275 : 262-264, 2018

18 Rosenblit PD, "Extreme atherosclerotic cardiovascular disease(ASCVD)risk recognition" 19 : 61-, 2019

19 Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease" 376 : 1713-1722, 2017

20 Mahtta D, "Evaluation of aspirin and statin therapy use and adherence in patients with premature atherosclerotic cardiovascular disease" 3 : e2011051-, 2020

21 문재철 ; 유소연 ; 고관표 ; 민경완 ; 신현호, "Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia" 한국지질동맥경화학회 9 (9): 162-171, 2020

22 Newman JD, "Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease" 184 : 114-120, 2017

23 Howard BV, "Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors" 29 : 391-397, 2006

24 Garber AJ, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary" 26 : 107-139, 2020

25 Briasoulis A, "Chronic kidney disease as a coronary artery disease risk equivalent" 15 : 340-, 2013

26 Mason JC, "Cardiovascular disease in patients with chronic inflammation : mechanisms underlying premature cardiovascular events in rheumatologic conditions" 36 : 482-489, 2015

27 Wanner C, "Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis" 353 : 238-248, 2005

28 김정선 ; Tung Hoang ; 부소영 ; 김지명 ; 최정화 ; 박은주 ; 이승민 ; 박은미 ; 민지연 ; 이인석 ; 윤소영, "Associations of Dietary Intake with Cardiovascular Disease, Blood Pressure, and Lipid Profile in the Korean Population: a Systematic Review and Meta-Analysis" 한국지질동맥경화학회 9 (9): 205-229, 2020

29 Emerging Risk Factors Collaboration, "Association of cardiometabolic multimorbidity with mortality" 314 : 52-60, 2015

30 Jellinger PS, "American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease" 23 : 1-87, 2017

31 Preiss D, "A systematic review of event rates in clinical trials in diabetes mellitus : the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design" 161 : 210-219, 2011

32 Mach F, "2019 ESC/EAS guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk" 290 : 140-205, 2019

33 이은정 ; 김현창 ; 김재현 ; 이은영 ; 김병진 ; 김은미 ; 송윤주 ; 임정현 ; 김혜진 ; 최성훈 ; 문민경 ; 나진오 ; 박광열 ; 오미선 ; 한상엽 ; 노정현 ; 이경희 ; 이상학 ; 홍순철 ; 정인경, "2018 Guidelines for the Management of Dyslipidemia in Korea" 한국지질동맥경화학회 8 (8): 78-131, 2019